Sampre Nutritions Ltd Falls to 52-Week Low of Rs 5.84 as Sell-Off Deepens

Price Decline and Market Context

The stock’s fall to Rs 5.84 represents a dramatic 86.2% drop from its 52-week high of Rs 42.33, underscoring the severity of the sell-off. This decline contrasts starkly with the broader market, where the Sensex gained 0.94% to trade at 77,460.46, buoyed by mega-cap stocks and indices such as the S&P BSE MidCap Select and NIFTY Midcap 50 hitting new 52-week highs. While the market rallies, Sampre Nutritions Ltd has diverged sharply, reflecting stock-specific pressures rather than sector-wide weakness. What is driving such persistent weakness in Sampre Nutritions when the broader FMCG sector is performing well?

Technical Indicators Signal Continued Pressure

The technical landscape for Sampre Nutritions Ltd remains firmly bearish. The stock trades below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—indicating sustained downward momentum. Weekly and monthly MACD and Bollinger Bands also signal bearish trends, while the KST indicator shows a mixed picture with a weekly bearish and monthly bullish stance. The Dow Theory readings are mildly bearish on both weekly and monthly timeframes. This technical configuration suggests limited near-term relief, with the data pointing to continued pressure on the stock price. Could the technical signals be hinting at a prolonged consolidation phase or further downside?

Valuation Metrics Reflect a Complex Picture

Despite the sharp price decline, Sampre Nutritions Ltd exhibits valuation ratios that are difficult to interpret given its micro-cap status and financial profile. The company’s Return on Capital Employed (ROCE) stands at a modest 2.6%, while the Enterprise Value to Capital Employed ratio is an attractive 0.6, suggesting the stock is trading at a discount relative to its capital base. The Price to Earnings (P/E) ratio is not explicitly stated due to the company’s loss-making status in some periods, but the PEG ratio of 0.1 indicates that earnings growth has outpaced the stock price decline. This valuation disconnect raises questions about whether the market is pricing in deeper concerns beyond the headline numbers. With the stock at its weakest in 52 weeks, should you be buying the dip on Sampre Nutritions or does the data suggest staying on the sidelines?

Financial Performance: Contrasting Signals

The latest financial results offer a contrasting narrative to the share price weakness. For the six months ended March 2026, Sampre Nutritions Ltd reported net sales of Rs 22.49 crores, reflecting a robust growth of 68.46% compared to previous periods. Net profit surged by 117.74%, reaching Rs 1.97 crores, marking the fourth consecutive quarter of positive earnings. The company’s debtors turnover ratio improved to 3.27 times, the highest recorded, indicating better collection efficiency. However, the average EBIT to interest coverage ratio remains weak at 0.47, signalling limited cushion to service debt obligations. Does the recent surge in profitability suggest a sustainable turnaround or is the market discounting other risks?

Long-Term Growth and Quality Metrics

Over the past five years, Sampre Nutritions Ltd has delivered an annual operating profit growth rate of 18.30%, which is moderate within the FMCG sector. However, the company’s long-term fundamental strength is considered weak, with an average ROCE of just 1.28%. The stock has underperformed the BSE500 index over the last three years, one year, and three months, generating a negative return of 42.03% in the past year alone, compared to the Sensex’s decline of 6.89%. Institutional holding remains low, with majority shareholders being non-institutional investors, which may limit the stock’s liquidity and support during downturns. How do these quality metrics influence the risk profile of Sampre Nutritions at current levels?

Key Data at a Glance

Balancing the Bear Case and Silver Linings

The steep decline in Sampre Nutritions Ltd shares reflects a combination of weak long-term fundamentals, poor debt servicing capacity, and sustained technical weakness. Yet, the recent quarterly results reveal a company that is growing sales and profits at a notable pace, with improving operational metrics such as debtor turnover. The valuation ratios suggest the stock is trading at a discount relative to its capital employed, although the micro-cap status and limited institutional support add layers of risk. Buy, sell, or hold at a 52-week low? The complete multi-factor analysis of Sampre Nutritions weighs all these signals.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →